The clinical and integrated management of COPD. An official document of AIMAR (Interdisciplinary Association for Research in Lung Disease), AIPO (Italian Association of Hospital Pulmonologists), SIMER (Italian Society of Respiratory Medicine), SIMG (Italian Society of General Medicine)

Multidisciplinary Respiratory Medicine

Volumn 9, Issue 1, 2014, Pages

  Bettoncelli, Germano ^a   Blasi, Francesco ^b   Brusasco, Vito ^c   Centanni, Stefano ^d   Corrado, Antonio ^e   De Benedetto, Fernando ^f   De Michele, Fausto ^g   Di Maria, Giuseppe U ^h   Donner, Claudio F ⁱ   Falcone, Franco ^j   Mereu, Carlo ^k   Nardini, Stefano ^l   Pasqua, Franco ^m   Polverino, Mario ⁿ   Rossi, Andrea ^o   Sanguinetti, Claudio M ^p  

^a Respiratory Diseases Ca GrandaOspedale Maggiore Milano Foundation UniversitàdegliStudi of Milan ^*

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c Respiratory Diseases UniversitàdegliStudi of Genua   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f SS Annunziata Hospital   (Italy)

^g CARDARELLI HOSPITAL   (Italy)

^h UNIVERSITY OF CATANIA   (Italy)

ⁱ Mondo Medico   (Italy)

^j Villa Torri Hospital   (Italy)

^k ASL 2   (Italy)

^l Vittorio Veneto General Hospital   (Italy)

^m IRCCSS   (Italy)

ⁿ ASL SA/3   (Italy)

^o University/General Hospital of Verona   (Italy)

^p SAN FILIPPO NERI HOSPITAL   (Italy)

more..

Author keywords

COPD; Integrated care; Management

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; OXYGEN; ROFLUMILAST; TIOTROPIUM BROMIDE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; EXERCISE; FORCED EXPIRATORY VOLUME; HEALTH EDUCATION; HOME CARE; HOSPITAL ADMISSION; HUMAN; INTEGRATED HEALTH CARE SYSTEM; MEDICAL SOCIETY; OXYGEN THERAPY; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PULMONARY REHABILITATION; QUALITY OF LIFE; TERMINAL CARE;

EID: 84902205684     PISSN: 1828695X     EISSN: 20496958     Source Type: Journal    
DOI: 10.1186/2049-6958-9-25     Document Type: Article

References (160)

1. Warsi A, Wang PS, LaValley MP, Avorn J, Solomon DH: Self management education programs in chronic disease: a systematic review and methodological critique of the literature. Arch Intern Med 2004, 164:1641-1649.
2. WHO Working Group Report: Therapeutic Patient Education: Continuing education programmes for healthcare providers in the field of prevention of chronic diseases. Copenhagen: WHO Regional Office for Europe; 1998.
3. Ministero Salute: Quaderno "Appropriatezza clinica, strutturale, tecnologica e operativa per la prevenzione, diagnosi e terapia dell'obesità e del diabete mellito".
4. Hogg JC, Macklem PT, Thurlbeck WM: Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968, 278:1355-1360.
5. Cosio M, Ghezzo H, Hogg JC, Corbin R, Loveland M, Dosman J, Macklem PT: The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 1978, 298:1277-1281.
6. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Paré PD: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Eng J Med 2004, 350:2645-2653.
7. Barnes PJ: Small airways in COPD. N Engl J Med 2004, 350:2635-2637.
8. Celli BR, Halbert RJ, Enright P, Brusasco V: Should we abandon FEV1 / FVC < 0.70 to detect airway obstruction? No/Yes. Chest 2010, 138:1037-1042.
9. Sorino C, Battaglia S, Scichilone N, Pedone C, Antonelli-Incalzi R, Sherrill D, Bellia V: Diagnosis of airway obstruction in the elderly: contribution of the SARA study. Int J COPD 2012, 7:389-395.
10. Mannino DM, Diaz-Guzman E: Interpreting lung function data using 80% predicted and fixed thresholds identifies patients at increate risk of mortality. Chest 2012, 141:73-80.
11. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk DD, Balter M, Ford G, Gervais A, Goldstein R, Hodder R, Kaplan A, Keenan S, Lacasse Y, Maltais F, Road J, Rocker G, Sin D, Sinuff T, Voduc N: Canadian Thoracic Society recommendation for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J 2007, 14:5b-32b.
12. Saetta M, Ghezzo H, Kim WD, King M, Angus GE, Wang NS, Cosio MG: Loss of alveolar attachments in smokers. A morphometric correlate of lung function impairment. Am Rev Respir Dis 1985, 132:894-900.
13. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, Rees PJ, on behalf of the Task Force: Optimal assessment and management of chronic obstructive pulmonary disease. ERS, consensus statement. EurRespir J 1995, 8:1398-1420.
14. Fiore MC: Treating tobacco use and dependance: 2008 Update. US Department of Health and Human Services, Ministerodella Salute. Istituto Superiore di Sanità. Linee guida cliniche per promuovere la cessazione dell'abitudine al fumo. Aggiornamento 2008.www.iss.it/ofad.
15. Tønnesen P, Carrozzi L, Fagerström KO, Gratziou C, Jimenez-Ruiz C, Nardini S, Viegi G, Lazzaro C, Campell IA, Dagli E, West R: Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. EurRespir J 2007, 29:390-417.
16. Implicazioni relative alla salute derivanti dall'uso della sigaretta elettronica: Documento di posizione congiunto dell'Associazione Italiana Pneumologi Ospedalieri (AIPO) e della Società Italiana di Medicina Respiratoria (SIMeR). Aprile 2013.www.aiponet.it; www.simernet.it.
17. Centre NCG: Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. London: National Clinical Guideline Centre; 2010. Available from: http://guidance.nice. org.uk/CG101/Guidance/pdf/English.
18. Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, Marciniuk DD, Denberg T, Schünemann H, Wedzicha W, MacDonald R, Shekelle P; American College of Physicians; American College of Chest Physicians; American Thoracic Society; European Respiratory Society: Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the ACP, ACCP, ATS and ERS. Ann Intern Med 2011, 155:179-191.
19. Vestbo J, Hurd SS, Agustì AA, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J RespirCrit Care Med 2013, 187:347-365.
20. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM: Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease. Am J RespirCrit Care Med 2008, 178:332-338.
21. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, for the UPLIFT Investigators: Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomized controlled trial. Lancet 2009, 374:1171-1178.
22. Troosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP, Decramer M; Uplift Investigators: Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. EurRespir J 2010, 36:65-73.
23. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, MacNee W, Miller BE, Silverman EK, Tal-Singer R, Wouters E, Rennard SI; ECLIPSE Investigators: Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011, 365:1184-1192.
24. Calverley PMA, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C; TRial of Inhaled STeroidsANd long-acting beta2 agonists study group: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003, 361:449-456.
25. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH investigators: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789.
26. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554.
27. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J: Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomized, placebo-controlled TORCH study. Respir Res 2009, 10:59-68.
28. Wedzicha JA, Calverley PMA, Seemugal TA, Hagan G, Ansari Z, Stockley RA, for the INSPIRE Investigators: The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J RespirCrit Care Med 2008, 177:19-26.
29. Kardos P, Wencker M, Glaab T, Vogelmeier C: Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J RespirCrit Care Med 2007, 175:144-149.
30. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM; POET-COPD Investigators: Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Eng J Med 2011, 364:1093-1103.
31. Decramer M, Chapman KR, Dahl R, Frith P, Devouassoux G, Fritscher C, Cameron R, Shoaib M, Lawrence D, Young D, McBryan D; INVIGORATE investigators: Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. LancetRespir Med 2013, 1(7) :524-533.
32. Wedzicha JA: Choice of bronchodilator therapy for patients with COPD. N Engl J Med 2011, 364:1167-1168.
33. Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P; TIOSPIR Investigators: Tiotropium Respimat inhaler and the risk of death in COPD. N Eng J Med 2013, 369:1491-1501.
34. Kerwin E, Hébert J, Gallagher N, Martin C, Overend T, Alagappan VK, Lu Y, Banerji D: Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 2012, 40:1106-1114.
35. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium: Tiotropium in combination with placebo, salmeterol, or fluticasone salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Ann Intern Med 2007, 146:545-555.
36. Short PM, Williamson PA, Elder DHJ, Lipworth SI, Schembri S, Lipworth BJ: The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD. Chest 2012, 141:81-86.
37. Camicilotti G, Bigazzi F, Paoletti M, Cestelli L, Lavorini F, Pistolesi M: Pulmonary function and sputum characteristics predict CT phenotype and severity of COPD. EurRespir J 2013, 42:626-635.
38. Ofir D, Laveneziana P, Webb KA, Lam YM, O'Donnel DE: Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J RespirCrit Care Med 2008, 177:622-629.
39. O'Donnell DE, Laveneziana P, Ora J, Webb KA, Lam YM, Ofir D: Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD. Thorax 2009, 64:216-223.
40. Tashkin DP, Fabbri LM: Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010, 11:149.
41. Rossi A, Khirani S, Cazzola M: Long-acting β2-agonist (LABA) in chronic obstructive pulmonary disease: efficacy and safety. Int J COPD 2008, 3:521-529.
42. Jones PW, Donohue JF, Nedelman J, Pascoe S, Pinaul G, Lassen C: Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir Res 2011, 12:161.
43. Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della Cioppa G; Formoterol in Chronic Obstructive Pulmonary Disease I Study Group: Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease study group. Am J RespirCrit Care Med 2001, 164:778-784.
44. Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J, Della Cioppa G; Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group: Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow release theophylline in the treatment of COPD. Chest 2002, 121:1058-1069.
45. Rossi A, Polese G: Indacaterol: a comprehensive review. Int J COPD 2013, 8:353-363.
46. Jones P, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, Segarra R, Caracta C, Garcia Gil E: Efficacy and safety of aclidinium bromide administered twice a day in patients with COPD; the ATTAIN study. EurRespir J 2012, 40:830-836.
47. Cazzola M, Page CP, Matera MG: Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. ExpOpinPharmacother 2013, 14:1205-1214.
48. Beier J, Kirsten AM, Mroz R, Segarra R, Chuecos F, Caracta C, Gil EG: Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb study. COPD 2013, 10:511-522.
49. Buhl R, Banerji D: Prophile of Glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J COPD 2012, 2:729-741.
50. COMBIVENT Inhalation Aerosol Study Group: In chronic obstructive pulmonary disease, a combination of ipratropium and alburerol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994, 105:1411-1419.
51. Benayoun S, Ernst P, Suissa S: The impact of combined inhaled bronchodilator therapy in the treatment of COPD. Chest 2001, 119:85-92.
52. van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJ: Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006, 129:509-517.
53. Rabe KF, Timmer W, Sagkriotis A, Viel K: Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008, 134:255-262.
54. van Noord JA, Buhl R, Laforce C, Martin C, Jones F, Dolker M, Overend T: QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 2010, 65: 1086-1091.
55. Karner C, Cates CJ: Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012, 4, CD008989.
56. Mahler DA, D'Urzo A, Bateman ED, Ozkan SA, White T, Peckitt C, Lassen C, Kramer B; INTRUST-1 and INTRUST-2 study investigators: Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomized, double-blind comparison. Thorax 2012, 67:781-788.
57. Tashkin DP, Ferguson GT: Combination bronchodilator in the management of chronic obstructive pulmonary disease. Respir Res 2013, 14:49.
58. Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, Chen H, Banerji D: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013, 1:51-60.
59. Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, D'Andrea P, Arrasate C, Chen H, Banerji D: Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013, 1:199-209.
60. Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, Banerji D: Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. EurRespir J 2013, 42:1484-1494.
61. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-1138.
62. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H: Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. EurRespir J 2003, 21:74-81.
63. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H: Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. EurRespir J 2003, 22:912-919.
64. Short PM, Williamson PA, Elder DH, Lipworth SI, Schembri S, Lipworth BJ: The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting - agonist therapy in COPD. Chest 2012, 141:81-86.
65. Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, Kessler R: Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J RespirCrit Care Med 2009, 180:741-750.
66. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbröker D, Bethke TD: Roflumilast -an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2005, 366:563-571.
67. Calverley PMA, Sanchez-Toril F, Mclvor A, Teichmann P, Bredenbröker D, Fabbri LM: Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J RespirCrit Care Med 2007, 176:154-161.
68. Calverley PMA, Rabe KF, Goehring U-M, Kristiansen S, Fabbri LM, Martinez F-J, for the M2-124 and M2-125 study groups: Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374:685-694.
69. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF; M2-127 and M2-128 study groups: Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet 2009, 374:695-703.
70. Beghè B, Rabe KF, Fabbri LM: Phosphodiesterase-4 inhibitor therapy for lung diseases. Am J RespirCrit Care Med 2013, 188:271-278.
71. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ: The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:1005-1012.
72. Celli BR, Calverley PM, Rennard SI, Wouters EF, Agusti A, Anthonisen N, Macnee W, Jones P, Pride N, Rodriguez-Roisin R, Rossi A, Wanner A: Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. Respir Med 2005, 99:1546-1554.
73. Funk GC, Kirchheiner K, Burghuber OC, Hartl S: BODE index versus GOLD classification for explaining anxious and depressive symptoms in patients with COPD - a cross-sectional study. Respir Res 2009, 10:1.
74. Jones RC, Donaldson GC, Chavannes NH, Kida K, Dickson-Spillmann M, Harding S, Wedzicha JA, Price D, Hyland ME: Derivation and validation of a composite index of severity in chronic obstructive pulmonary diseases. Am J RespirCrit Care Med 2009, 180:1189-1195.
75. Puhan MA, Garcia-Aymerich J, Frey M, terRiet G, Antó JM, Agustí AG, Gómez FP, Rodríguez-Roisín R, Moons KG, Kessels AG, Held U: Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009, 374:704-711.
76. Rossi A, Zanardi E: E pluribus plurima: Multidimensional indices and clinical phenotypes in COPD. Respir Res 2011, 12:15.
77. Long term domiciliary oxygen therapy in chronic hypoxic corpulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981, 1:681-686.
78. Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980, 93:391-398.
79. Plant PK, Owen JL, Elliott MW: One year period prevalence study of respiratory acidosis in acute exacerbations of COPD: implications for the provision of non-invasive ventilation and oxygen administration. Thorax 2000, 55:550-554.
80. Corrado A, Renda T, Bertini S: Long-Term Oxygen Therapy in COPD: evidences and open questions of current indications. MonaldiArchChestDis 2010, 73:34-43.
81. Linee Guida "Insufficienza Respiratoria" Regione Toscana. 2010.
82. Linee Guida per la Ossigenoterapia a lungo termine (OTLT). Aggiornamento anno 2004. Rassegna di Patologia dell'Apparato Respiratorio 2004, 19:206-219.
83. Guyatt GH, Nonoyama M, Lacchetti C, Goeree R, McKim D, Heels-Ansdell D, Goldstein R: A randomized trial of strategies for assessing eligibility for long-term domiciliary oxygen therapy. Am J RespirCrit Care Med 2005, 172:573-580.
84. Clini E, Sturani C, Rossi A, Viaggi S, Corrado A, Donner CF, Ambrosino N; Rehabilitation and Chronic Care Study Group, Italian Association of Hospital Pulmonologists (AIPO): The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. EurRespir J 2002, 20:529-538.
85. Criner GJ: Lung volume reduction as an alternative to transplantation for COPD. Clin Chest Med 2011, 32:379-397.
86. Garrity ER, Moore J, Mulligan MS, Shearon TH, Zucker MJ, Murray S: Heart and lung transplantation in the United States, 1996-2005. Am J Transplant 2007, 7:1390-1403.
87. Cai J: Double- and single-lung transplantation: an analysis of twenty years of OPTIN/UNOS registry data. ClinTranspl 2007:1-8.
88. ACCP/AACVPR: Pulmonary rehabilitation. Joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest 2007, 131:4-42.
89. ATS/ERS Task Force: Standards for the Diagnosis and Treatment of Patients with COPD. 2004. available on line, www.ers-education.org.
90. British Thoracic Society: Guidelines for the physiotherapy management of the adult medical, spontaneously breathing patients. Thorax 2009, 64(suppl):1-51.
91. British Thoracic Society: Pulmonary rehabilitation. Thorax 2001, 56:827-834.
92. Ambrosino N, Vitacca M, Rampulla C: Percorsi riabilitativi nelle malattie respiratorie. Fondazione Maugeri IRCCS "I Documenti" 1997, (no 11).
93. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Carone M, Celli B, Engelen M, Fahy B, Garvey C, Goldstein R, Gosselink R, Lareau S, MacIntyre N, Maltais F, Morgan M, O'Donnell D, Prefault C, Reardon J, Rochester C, Schols A, Singh S, Troosters T; ATS/ERS Pulmonary Rehabilitation Writing Committee: American Thoracic Society/European Respiratory Society: Statement on pulmonary rehabilitation. Am J RespirCrit Care Med 2006, 173:1390-1413.
94. Associazione Italiana Pneumologi Ospedalieri: Raccomandazioni sulla Riabilitazione Respiratoria. RassPatol App Respir 2007, 22:264-288.
95. European Society of Intensive Care Medicine: Physiotherapy for adult patients with critical illness: recommendations of ERS and ESICM Task Force on Physiotherapy for critically ill patients. Intensive Care Medicine 2008, 34:1188-1199.
96. California pulmonary Rehabilitation Collaborative Group: Effects of pulmonary rehabilitation on dyspnea, quality of life, and healthcare costs in California. J CardiopulmRehabil 2004, 24:52-62.
97. Casaburi R, ZuWallack R: Pulmonary rehabilitation for management of chronic obstructive pulmonary disease. N Engl J Med 2009, 360:1329-1335.
98. Nici L, Raskin J, Rochester CL, Bourbeau JC, Carlin BW, Casaburi R, Celli BR, Cote C, Crouch RH, Diez-Morales LF, Donner CF, Fahy BF, Garvey C, Goldstein R, Lane-Reticker A, Lareau SC, Make B, Maltais F, McCormick J, Morgan MD, Ries A, Troosters T, ZuWallack R: Pulmonary rehabilitation: what we know and what we need to know. J CardiopulmRehabilPrev 2009, 29:141-151.
99. Lacasse Y, Goldstein R, Lasserson TJ, Martin S: Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006, 4, CD003793.
100. Puhan M, Scharplatz M, Troosters T, Walters EH, Steurer J: Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2009, 1, CD005305.
101. Troosters T, Casaburi R, Gosselink R, Decramer M: Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J RespirCrit Care Med 2005, 172:19-38.
102. Troosters T, Gosselink R, Janssens W, Decramer M: Exercise training and pulmonary rehabilitation: new insights and remaining challenges. EurRespir Rev 2010, 19(115):24-29.
103. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-1138.
104. Trappenburg JCA, van Deventer AC, Troosters T, Verheij TJ, Schrijvers AJ, Lammers JW, Monninkhof EM: The impact of using different symptom-based exacerbation algorithms in patients with COPD. EurRespir J 2011, 37:1260-1268.
105. Mackay AL, Donaldson GC, Patel ARC, Jones PW, Hurst JR, Wedzicha JA: Usefulness of the chronic obstructive pulmonary disease assessment test to evaluate severity of COPD exacerbations. Am J RespirCrit Care Med 2012, 185:1218-1224.
106. Seemugal TAR, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA: Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J RespirCrit Care Med 2000, 161:1608-1613.
107. Donaldson GC, Seemugal TAR, Bhowmik A, Wedzicha A: Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002, 57:847-852.
108. Anzueto A, Leimer I, Kesten S: Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J COPD 2009, 4:245-251.
109. Tillie-Leblond I, Marquette CH, Perez T, Scherpereel A, Zanetti C, Tonnel AB, Remy- Jardin M: Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 2006, 144:390-396.
110. Rizkallah J, Man SFP, Sin DD: Prevalence of pulmonary embolism in acute exacerbations of COPD. A systematic review and meta-analysis. Chest 2009, 135:786-793.
111. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, Fabbri LM, Johnston SL: Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J RespirCrit Care Med 2006, 173:1114-1121.
112. Di Marco F, Verga M, Santus P, Morelli N, Cazzola M, Centanni S: Effect of formoteroltiotropium and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease. A pilot study. Respir Med 2006, 100:1925-1932.
113. Albert RK, Martin TR, Lewis SW: Controlled clinical trial on methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med 1980, 92:753-758.
114. Davies L, Angus RM, Calverley PM: Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet 1999, 354:456-460.
115. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA: Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999, 340:1941-1947.
116. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987, 106:196-204.
117. Saint S, Bent S, Vittinghoff E, Grady D: Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995, 273:957-960.
118. Stockley RA, O'Brien C, Pye A, Hill SL: Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000, 117:1638-1645.
119. Roede BM, Bresser P, Prins JM, Schellevis F, Verheij TJ, Bindels PJ: Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD. EurRespir J 2009, 33:282-288.
120. Daniels JMA, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WJ: Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J RespirCrit Care Med 2012, 181:150-157.
121. Celli BR, MacNee W, and committee members: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. EurRespir J 2004, 23:932-946.
122. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, et al: Optimal assessment and management of chronic obstructive pulmonary disease. ERS, consensus statement. EurRespir J 1995, 8:1398-1420.
123. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk DD, Balter M, Ford G, Gervais A, Goldstein R, Hodder R, Kaplan A, Keenan S, Lacasse Y, Maltais F, Road J, Rocker G, Sin D, Sinuff T, Voduc N: Canadian Thoracic Society recommendation for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J 2007, 14:5b-32b.
124. Nava S, Fanfulla F: Ventilazione meccanica non invasiva. Come, quando e perché. Milano: Springer-Verlag Italia; 2010.
125. Statement ATS: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J RespirCrit Care Med 1995, 5:S77-S120.
126. ATS ERS: statement. EurRespir J 2004, 23:932-946.
127. Corrado A, Roussus C, Ambrosino N, Confalonieri M, Cuvelier A, Elliott M, Ferrer M, Gorini M, Gurkan O, Muir JF, Quareni L, Robert D, Rodenstein D, Rossi A, Schoenhofer B, Simonds AK, Strom K, Torres A, Zakynthinos S; European Respiratory Society Task Force on epidemiology of respiratory intermediate care in Europe: Respiratory intermediate care units: an European survey. EurRespir J 2002, 20:1343-1350.
128. Corrado A, Ambrosino N, Cavalli A, Sturani C: Unità di terapia intensiva respiratoria: update. RassPatAppRespir 2004, 19:18-34.
129. Linee Guida "Insufficienza Respiratoria" Regione Toscana.2010.
130. Statement on Home Care for Patients with Respiratory Disorders: This official statement of the American Thoracic Society was approved by the ATS board of Directors December 2005. Am J RespirCrit Care Med 2005, 171:1443-1464.
131. Farrero E, Escarrabill J, Prats E, Maderal M, Manresa E: Impact of a hospital-based home-care program on the management of COPD patients receiving long-term oxygen therapy. Chest 2001, 119:364-369.
132. Hermiz O, Comino E, Marks G, Daffurn K, Wilson S, Harris M: Randomised controlled trial of home based care of patients with chronic obstructive pulmonary disease. BMJ 2002, 325:938-940.
133. Lanken PN, Terry PB, Delisser HM, Fahy BF, Hansen-Flaschen J, Heffner JE, Levy M, Mularski RA, Osborne ML, Prendergast TJ, Rocker G, Sibbald WJ, Wilfond B, Yankaskas JR; ATS End-of-Life Care Task Force: An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J RespirCrit Care Med 2008, 177:912-927.
134. Curtis JR: Palliative and end of life care for patients with severe COPD. EurRespir J 2008, 32:796-803.
135. Cure palliative dei pazienti con patologie respiratorie croniche avanzate non oncologiche. 2011. Position Paper AIPO-SIAARTI-ARIR.
136. D.M. del MURST 20/4/90.
137. Piano Sanitario Nazionale 2011-2013. www.salute.gov.it
138. Jaana M, Paré G, Sicotte C: Home telemonitoring for respiratory conditions: a systematic review. Am J Manag Care 2009, 15:313-320.
139. Linee Guida "Insufficienza Respiratoria" Regione Toscana. 2010.
140. Statement ATS: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J RespirCrit Care Med 1995, 5:S77-S121.
141. Statement on Home Care for Patients with Respiratory Disorders: This official statement of the American Thoracic Society was approved by the ATS board of Directors December 2005. Am J RespirCrit Care Med 2005, 171:1443-1464.
142. Corrado A, Roussus C, Ambrosino N, Confalonieri M, Cuvelier A, Elliott M, Ferrer M, Gorini M, Gurkan O, Muir JF, Quareni L, Robert D, Rodenstein D, Rossi A, Schoenhofer B, Simonds AK, Strom K, Torres A, Zakynthinos S; European Respiratory Society Task Force on epidemiology of respiratory intermediate care in Europe: Respiratory intermediate care units: an European survey. EurRespir J 2002, 20:1343-1350.
143. Farrero E, Escarrabill J, Prats E, Maderal M, Manresa F: Impact of a hospital-based homecare program on the management of COPD patients receiving long-term oxygen therapy. Chest 2001, 119:364-369.
144. Hermiz O, Comino E, Marks G, Daffurn K, Wilson S, Harris M: Randomised controlled trial of homebased care of patients with chronic obstructive pulmonary disease. BMJ 2002, 325:938-940.
145. Jaana M, Paré G, Sicotte C: Home telemonitoring for respiratory conditions: a systematic review. Am J Manag Care 2009, 15:313-320.
146. Dal Negro RW, Goldberg AI (Eds): Home Long-Term Oxygen Treatment in Italy. The Additional Value of Telemedicine". Berlin Heidelberg. Springer Publ; 2005:71-85.
147. Vitacca M, Mazzù M, Scalvini S: Socio-technical and organizational challenges to wider e-Health implementation. ChronRespir Dis 2009, 6:91.
148. Vitacca M, Bianchi L, Guerra A, Fracchia C, Spanevello A, Balbi B, Scalvini S: Teleassistance in chronic respiratory failure patients: a randomised clinical trial. EurRespir J 2009, 33:411-418.
149. Vitacca M, Comini L, Tentorio M,Assoni G, Trainini D, Fiorenza D, Morini R, Bruletti G, Scalvini S:A pilot trial of telemedicine-assisted, integrated care for patients with advanced amyotrophic lateralsclerosis and their caregivers. J TelemedTelecare 2010, 16:83-88.
150. Piano SanitarioNazionale 2011-2013.
151. D.M. del MURST 20/4/90.
152. Lanken PN, Terry PB, Delisser HM, Fahy BF, Hansen-Flaschen J, Heffner JE, Levy M, Mularski RA, Osborne ML, Prendergast TJ, Rocker G, Sibbald WJ, Wilfond B, Yankaskas JR; ATS End-of-Life Care Task Force: An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J RespirCrit Care Med 2008, 177:912-927.
153. Curtis JR: Palliative and end of life care for patients with severe COPD. EurRespir J 2008, 32:796-803.
154. Cure palliative dei pazienti con patologie respiratorie croniche avanzate non oncologiche. 2011. Position Paper AIPO-SIAARTI-ARIR.
155. GOLD Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2011.
156. Centre NCG: Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. London: National Clinical Guideline Centre; 2010. Available from: http://guidance.nice. org.uk/CG101/Guidance/pdf/English.
157. Celli B, MacNee W, and committee members: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. EurRespir J 2004, 23:932-946.
158. Brusasco V, Crapo R, Viegi G; American Thoracic Society; European Respiratory Society: Coming together: the ATS/ERS consensus on clinical pulmonary function testing. EurRespir J 2005, 26:1-2. 153-161; 319-338; 511-522; 720-735; 948-968.
159. Screening for chronic obstructive pulmonary disease using spirometry: U.S. preventive services task force recommendation statement. Ann Intern Med 2008, 148:529-534.
160. Qaseem A, Wilt TJ, Weiberger SE, Hanania NA, Criner G, van der Molen T, Marciniuk DD, Denberg T, Schünemann H, Wedzicha W, MacDonald R, Shekelle P; American College of Physicians; American College of Chest Physicians; American Thoracic Society; European Respiratory Society: Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the ACP, ACCP, ATS and ERS. Ann Intern Med 2011, 155:179-191.